These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21946261)

  • 1. Kinetic efficiency: the missing metric for enhancing compound quality?
    Holdgate GA; Gill AL
    Drug Discov Today; 2011 Nov; 16(21-22):910-3. PubMed ID: 21946261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
    Meanwell NA
    Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of binding kinetics in therapeutically useful drug action.
    Swinney DC
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):31-9. PubMed ID: 19152211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving molecules using multi-objective optimization: applying to ADME/Tox.
    Ekins S; Honeycutt JD; Metz JT
    Drug Discov Today; 2010 Jun; 15(11-12):451-60. PubMed ID: 20438859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative variables in drug discovery: promises and challenges.
    Abad-Zapatero C; Champness EJ; Segall MD
    Future Med Chem; 2014 Apr; 6(5):577-93. PubMed ID: 24649959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of PBPK modelling in drug discovery and development at Pfizer.
    Jones HM; Dickins M; Youdim K; Gosset JR; Attkins NJ; Hay TL; Gurrell IK; Logan YR; Bungay PJ; Jones BC; Gardner IB
    Xenobiotica; 2012 Jan; 42(1):94-106. PubMed ID: 22035569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations.
    Shultz MD
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5992-6000. PubMed ID: 24054120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics for Drug Discovery: an industry-driven effort to target drug residence time.
    Schuetz DA; de Witte WEA; Wong YC; Knasmueller B; Richter L; Kokh DB; Sadiq SK; Bosma R; Nederpelt I; Heitman LH; Segala E; Amaral M; Guo D; Andres D; Georgi V; Stoddart LA; Hill S; Cooke RM; De Graaf C; Leurs R; Frech M; Wade RC; de Lange ECM; IJzerman AP; Müller-Fahrnow A; Ecker GF
    Drug Discov Today; 2017 Jun; 22(6):896-911. PubMed ID: 28412474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 12. Emerging applications of kinetic biomarkers in preclinical and clinical drug development.
    Turner SM; Hellerstein MK
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):115-26. PubMed ID: 15679179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free versus total ligand-binding assays: points to consider in biotherapeutic drug development.
    Yang J; Quarmby V
    Bioanalysis; 2011 Jun; 3(11):1163-5. PubMed ID: 21649490
    [No Abstract]   [Full Text] [Related]  

  • 14. [Ligand efficiency and lead optimization].
    Guo ZR
    Yao Xue Xue Bao; 2013 Dec; 48(12):1755-62. PubMed ID: 24689231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond profiling: using ADMET models to guide decisions.
    Segall M; Champness E; Obrezanova O; Leeding C
    Chem Biodivers; 2009 Nov; 6(11):2144-51. PubMed ID: 19937845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand efficiency and fragment-based drug discovery.
    Bembenek SD; Tounge BA; Reynolds CH
    Drug Discov Today; 2009 Mar; 14(5-6):278-83. PubMed ID: 19073276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H
    Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal experimental design for assessment of enzyme kinetics in a drug discovery screening environment.
    Sjögren E; Nyberg J; Magnusson MO; Lennernäs H; Hooker A; Bredberg U
    Drug Metab Dispos; 2011 May; 39(5):858-63. PubMed ID: 21289074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs.
    Perola E
    J Med Chem; 2010 Apr; 53(7):2986-97. PubMed ID: 20235539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward a new age of cellular pharmacokinetics in drug discovery.
    Zhou F; Zhang J; Li P; Niu F; Wu X; Wang G; Roberts MS
    Drug Metab Rev; 2011 Aug; 43(3):335-45. PubMed ID: 21395404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.